A share price of Gilead Sciences, Inc [GILD] is currently trading at $92.49, down -1.63%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GILD shares have gain 2.21% over the last week, with a monthly amount glided 3.33%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on November 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $110. Previously, Citigroup started tracking the stock with Buy rating on November 14, 2024, and set its price target to $125. On November 08, 2024, downgrade downgraded it’s rating to Hold. Leerink Partners upgraded its rating to a Outperform and increased its price target to $96 on October 21, 2024. Bernstein initiated its recommendation with a Outperform and recommended $105 as its price target on October 17, 2024. Wells Fargo upgraded its rating to Overweight for this stock on October 07, 2024, and upped its price target to $100. In a note dated July 08, 2024, Raymond James upgraded an Outperform rating on this stock but restated the target price of $93.
Gilead Sciences, Inc experienced fluctuations in its stock price throughout the past year between $62.07 and $98.90. Currently, Wall Street analysts expect the stock to reach $81.77 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $92.49 at the most recent close of the market. An investor can expect a potential drop of -11.59% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Trailing Twelve Months sales for Gilead Sciences, Inc [NASDAQ:GILD] were 28.27B which represents 7.05% growth. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.3%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.01 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 91.84 points at the first support level, and at 91.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 93.77, and for the 2nd resistance point, it is at 95.04.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Gilead Sciences, Inc [NASDAQ:GILD] is 1.26. In addition, the Quick Ratio stands at 1.10 and the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 4.08, the price to book ratio is 6.24 and price to earnings (TTM) ratio is 1042.73.
Transactions by insiders
Recent insider trading involved Dickinson Andrew D, Chief Financial Officer, that happened on Nov 29 ’24 when 0.25 million shares were sold. Chief Medical Officer, Parsey Merdad completed a deal on Nov 27 ’24 to sell 0.16 million shares. Meanwhile, Officer ANDREW DICKINSON bought 0.25 million shares on Nov 29 ’24.
